Telomerase and telomeres: From basic biology to cancer treatment

Cancer Investigation

Volumn 20, Issue 1, 2002, Pages 82-101

  Helder, Marco N ^a   Wisman, G Bea A ^a   Van der Zee, Ate G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cancer treatment; hTERT; hTR; Telomerase; Telomere

Indexed keywords

2',3' DIDEOXYADENOSINE; 2',3' DIDEOXYGUANOSINE; 2',3' DIDEOXYTHYMIDINE; 7 DEAZA 2' DEOXYADENOSINE 5' TRIPHOSPHATE; 7 DEAZA 2' DEOXYGUANOSINE 5' TRIPHOSPHATE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CELL DNA; DIDANOSINE; DIMETHYL SULFOXIDE; G QUADRUPLEX STABILIZING SUBSTANCE; GUANINE ARABINOSIDE; HOLOENZYME; NUCLEOSIDE DERIVATIVE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PHORBOL 13 ACETATE 12 MYRISTATE; RETINOIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TELOMERASE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADVANCED CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CELL DIVISION; CELL IMMORTALIZATION; CELL SURVIVAL; CONFERENCE PAPER; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; NONHUMAN; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ASSEMBLY; SOMATIC CELL; SUICIDE GENE THERAPY; TELOMERE;

EID: 0036169550     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120000370     Document Type: Conference Paper

References (135)

1. Mechanisms of drug resistance
2. The serial cultivation of human diploid cell strains
3. Telomeres shorten during ageing of human fibroblasts
4. The emerging p53 gene family
5. Regulation of the p53 protein by the MDM2 oncoprotein - Thirty-eighth G.H.A. clowes memorial award lecture
6. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth
7. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts
8. Defining the molecular mechanisms of human cell immortalization
9. Limited and unlimited growth of SV40-transformed cells from human diploid MRC-5 fibroblasts
10. Telomere dynamics and telomerase activity in in vitro immortalised human cells
11. Reversing time: Origin of telomerase
12. Extension of life-span by introduction of telomerase into normal human cells
13. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas
14. Reconstitution of human telomerase activity in vitro
15. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT
16. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase
17. The RNA component of human telomerase
18. Telomerase catalytic subunit homologs from fission yeast and human
19. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization
20. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types
21. A mammalian telomerase-associated protein
22. The telomerase reverse transcriptase: Components and regulation
23. The telomerase RNA pseudoknot is critical for the stable assembly of a catalytically active ribonucleoprotein
24. Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA
25. Inhibition of telomerase limits the growth of human cancer cells
26. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase
27. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype
28. Interaction of recombinant tetrahymena telomerase proteins p80 and p95 with telomerase RNA and telomeric DNA substrates
29. TLP1: A gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family
30. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids
31. Functional requirement of p23 and Hsp90 in telomerase complexes
32. Gene structure and expression of the mouse dyskeratosis congenita gene, dkc1
33. The box H+ACA snoRNAs carry Cbf5p, the putative rRNA pseudouridine synthase
34. A telomerase component is defective in the human disease dyskeratosis congenita
35. In vitro assembly of human H/ACA Small nucleolar RNPs reveals unique features of U17 and telomerase RNAs
36. Telomerase-mediated telomere addition in vivo requires DNA primase and DNA polymerases alpha and delta
37. The function of DNA polymerase alpha at telomeric G tails is important for telomere homeostasis
38. TRF1 binds a bipartite telomeric site with extreme spatial flexibility
39. hnRNP A2/B1 binds specifically to single stranded vertebrate telomeric repeat TTAGGGn
40. Nuclear proteins that bind the pre-mRNA 3′ splice site sequence r(UUAG/G) and the human telomeric DNA sequence d(TTAGGG)n
41. Crystal structure of the two-RRM domain of hnRNP A1 (UPI) complexed with single-stranded telomeric DNA
42. Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase
43. A human telomeric protein
44. Telomeric localization of TRF2, a novel human telobox protein
45. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2
46. TRF1 is a dimer and bends telomeric DNA
47. TRF1 promotes parallel pairing of telomeric tracts in vitro
48. Control of telomere length by the human telomeric protein TRF1
49. TRF2 protects human telomeres from end-to-end fusions
50. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres
51. Tankyrase promotes telomere elongation in human cells
52. TIN2, a new regulator of telomere length in human cells
53. Mammalian telomeres end in a large duplex loop
54. Processing of telomeric DNA ends requires the passage of a replication fork
55. New antiretrovirals and new combinations
56. Telomerase targeting in cancer treatment: New developments
57. Preferential incorporation of 3′-azido-2′,3′-dideoxythymidine into telomeric DNA and Z-DNA-containing regions of Chinese hamster ovary cells
58. The effects of telomerase inhibitors on lymphocyte function
59. Nucleoside transport and its significance for anticancer drug resistance
60. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies
61. Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection
62. Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity
63. Downregulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated protein
64. Supression of telomerase activity in HL60 cells after treatment with differentiating agents
65. Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines
66. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by retinoic acids
67. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer
68. Cloning and characterization of human and mouse telomerase rna gene promoter sequences
69. The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter
70. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene
71. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells
72. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT)
73. Methylation of the human telomerase gene CpG island
74. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene
75. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription
76. Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA
77. Telomerase reverse transcriptase gene is a direct target of c-myc but is not functionally equivalent in cellular transformation
78. Myc activates telomerase
79. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT)
80. Identification of mad as a repressor of the human telomerase (hTERT) gene
81. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1
82. Estrogen activates telomerase
83. Effects of tamoxifen on telomerase activity in breast carcinoma cell lines
84. Antisense of oligonucleotides and the inhibition of oncogene expression
85. Antisense telomerase treatment: Induction of two distinct pathways, apoptosis and differentiation
86. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis
87. Inhibition of human telomerase by a retrovirus expressing telomeric antisense RNA
88. Effect of antisense human telomerase RNA transfection on the growth of human gastric cancer cell lines
89. Targeting RNA for degradation with a (2′-5′)oligoadenylate-antisense chimera
90. Inhibition of human telomerase by 2′-O-methyl-RNA
91. Inhibition of human telomerase activity by peptide nucleic acids
92. Cellular delivery of peptide nucleic acids and inhibition of human telomerase
93. Specific inhibition of human telomerase activity by transfection reagent, FuGENE6-antisense phosphorothioate oligonucleotide complex in HeLa cells
94. Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides
95. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells
96. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo
97. Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning
98. Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides
99. Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells
100. Synthesis and membrane permeability of PNA-peptide conjugates
101. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo
102. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death
103. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA
104. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component
105. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells
106. The catalytic subunit of telomerase protects neurons against amyloid beta-peptide-induced apoptosis
107. The catalytic subunit of telomerase is expressed in developing brain neurons and serves a cell survival-promoting function
108. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit
109. Telomerase is controlled by protein kinase C alpha in human breast cancer cells
110. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines
111. Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos
112. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells
113. Inhibition of unwinding of G-quadruplex structures by Sgs 1 helicase in the presence of n,n(-bis[2-(1-piperidino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide, a G-quadruplex-interactive ligand
114. NMR-based model of a telomerase-inhibiting compound bound to G-quadruplex DNA
115. HSV-TK 'suicide' gene therapy using human telomerase reverse transcriptase (hTERT) promoter
116. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
117. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
118. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells
119. Specific association of human telomerase activity with immortal cells and cancer
120. Is telomerase a universal cancer target?
121. A survey of telomerase activity in human cancer
122. Telomerase activity in normal and malignant hematopoietic cells
123. Telomerase activity in normal leukocytes and in hematologic malignancies
124. Telomerase activity concentrates in the mitotically active segments of human hair follicles
125. Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes
126. Telomerase activity in normal human epithelial cells
127. Telomerase activity in human endometrium
128. Telomerase activity of normal tissues and neoplasms in rat colon carcinogenesis induced by methylazoxymethanol acetate and its difference from that of human colonic tissues
129. T cell telomere length in HIV-1 infection: No evidence for increased CD4+ T cell turnover
130. Telomere shortening may contribute to aging and cancer: A perspective
131. Telomerase and cancer: Revisiting the telomere hypothesis
132. Telomerase: Immortality enzyme or oncogene?
133. Agents that target telomerase and telomeres
134. Clinical evaluation of biologically targeted drugs: Obstacles and opportunities